Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Molecular Outcome of Chronic Myeloid Leukemia Affected Patients Not in Deep Molecular Response: The “Others” from the Gimema Labnet Network

Blood (2024) 144 (Supplement 1): 992.

https://doi.org/10.1182/blood-2024-210201

Published: 2024

Journal Articles

Digital Twins As Control Groups to Accelerate Assessment of Safety and Efficacy of Novel Treatment Strategies in Ph-Negative Acute Lymphoblastic Leukemia

Alfonso Piciocchi, Monica Messina, Giovanni Marsili, Marta Cipriani, Francesca Paola Paoloni, Davide Lazzarotto, Anna Candoni, Alessandro Rambaldi, Matteo Leoncin, Paola Fazi, Marco Vignetti, Robin Foà, Sabina Chiaretti

Blood (2024) 144 (Supplement 1): 274.

https://doi.org/10.1182/blood-2024-200643

Published: 2024

Journal Articles

Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial

Blood (2024) 144 (Supplement 1): 2836.

https://doi.org/10.1182/blood-2024-210731

Published: 2024

Journal Articles

Evaluating the Impact of Cross-over from Imatinib to Nilotinib on the Overall Survival in Chronic Myeloid Leukemia Using Inverse Probability of Censoring Weighting: Results from the Gimema Sustrenim Study

Alfonso Piciocchi, Giovanni Marsili, Ylenia Belperio, Monica Messina, Francesca Paola Paoloni, Stefano Soddu, Isabella Capodanno, Rosaria Sancetta, Elisabetta Abruzzese, Alessandro Pulsoni, Monia Lunghi, Giovanni Caocci, Fausto Castagnetti, Paola Fazi, Marco Vignetti, Massimo Breccia, Fabrizio Pane

Blood (2024) 144 (Supplement 1): 4530.

https://doi.org/10.1182/blood-2024-198366

Published: 2024

Journal Articles

Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial

Blood (2023) 142 (Supplement 1): 826.

https://doi.org/10.1182/blood-2023-174973

Published: 2023

Journal Articles

LONG-TERM Results of the Frontline Dasatinib/Blinatumomabprotocol (D-ALBA, GIMEMA LAL2116) for Adult Ph+ Acutelymphoblastic Leukemia

Robin Foà, Renato Bassan, Loredana Elia, Alfonso Piciocchi, Stefano Soddu, Monica Messina, Felicetto Ferrara, Monia Lunghi, Antonino Mulè, Massimiliano Bonifacio, Nicola Fracchiolla, Prassede Salutari, Paola Fazi, Anna Guarini, Alessandro Rambaldi, Sabina Chiaretti

Blood (2023) 142 (Supplement 1): 4250.

https://doi.org/10.1182/blood-2023-187773

Published: 2023

Journal Articles

A Propensity Score Weighting Analysis Emphasizes the Progress of the Gimema Approach in Adult Ph-Positive Acute Lymphoblastic Leukemia in the TKI Era

Alfonso Piciocchi, Sabina Chiaretti, Marta Cipriani, Monica Messina, Loredana Elia, Irene Della Starza, Antonella Vitale, Paola Fazi, Marco Vignetti, Robin Foa

Blood (2023) 142 (Supplement 1): 4200.

https://doi.org/10.1182/blood-2023-179102

Published: 2023

Journal Articles

International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia (SUSTRENIM trial): Analysis of the Eligibility to Treatment Discontinuation

Blood (2023) 142 (Supplement 1): 3169.

https://doi.org/10.1182/blood-2023-182220

Published: 2023

Journal Articles

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Blood (2023) 142 (Supplement 1): 1905.

https://doi.org/10.1182/blood-2023-181597

Published: 2023

Journal Articles

A Snapshot of the Management of Chronic Lymphocytic Leukemia in Italy. Preliminary Analysis on over 3000 Patients Enrolled in the Gimema CLL2121 Trial

Blood (2023) 142 (Supplement 1): 6544.

https://doi.org/10.1182/blood-2023-188454

Published: 2023

Journal Articles

Comparison between Dasatinib-Blinatumomab Vs Ponatinib-Blinatumomab Chemo-Free Strategy for Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia Patients. Preliminary Results of the Gimema ALLL2820 Trial

Blood (2023) 142 (Supplement 1): 4249.

https://doi.org/10.1182/blood-2023-189632

Published: 2023

Journal Articles

The Addition of Venetoclax to Induction Chemotherapy in No Low-Risk AML Patients: A Propensity Score-Matched Analysis of the Gimema AML1718 and AML1310 Trials

Alfonso Piciocchi, Monica Messina, Marta Cipriani, Francesca Paoloni, Giorgia Simonetti, Raffaele Palmieri, Giovanni Marconi, Francesco Buccisano, Paola Fazi, Marco Vignetti, Giovanni Martinelli, Adriano Venditti

Blood (2022) 140 (Supplement 1): 137–138.

https://doi.org/10.1182/blood-2022-158890

Published: 2022

Journal Articles

The Added Value of Multi-State Modelling in Acute Myeloid Leukemia: The Gimema AML1310 Study Post-Hoc Analysis

Alfonso Piciocchi, Valentina Arena, Monica Messina, Sonia Maria Orlando, Raffaele Palmieri, Luca Maurillo, Maria Ilaria Del Principe, Paola Fazi, Marco Vignetti, Francesco Buccisano, Adriano Venditti

Blood (2022) 140 (Supplement 1): 3192–3193.

https://doi.org/10.1182/blood-2022-158942

Published: 2022

Journal Articles

Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 6119–6121.

https://doi.org/10.1182/blood-2022-157937

Published: 2022

Journal Articles

Prognostic Impact of t(4;11)(q21;q23)/ KMT2A-AFF1 -Positivity in 926 BCR-ABL1 -Negative B-Lineage Acute Lymphoblastic Leukemia Patients Treated in Gimema Clinical Trials Since 1996

Alfonso Piciocchi, Monica Messina, Loredana Elia, Bs, Antonella Vitale, MD, Stefano Soddu, Anna Maria Testi, MD, Sabina Chiaretti, MD PhD, Marco Mancini, MD, Giorgina Specchia, MD, Antonio Spadano, MD, Mauro Krampera, Roberto Cairoli, MD, Francesco Di Raimondo, MD, Felicetto Ferrara, MD, Giuseppe Cimino, MD, Renato Bassan, MD, Paola Fazi, MD, Marco Vignetti, MD

Blood (2019) 134 (Supplement_1): 1469.

https://doi.org/10.1182/blood-2019-121977

Published: 2019

Journal Articles

The Validation of the BCR/ABL1 -like Predictor across Laboratories Shows Reproducibility of Results

Sabina Chiaretti, MD PhD, Taherinasab Akram, Canichella Martina, Monica Messina, Alfonso Piciocchi, Cyril Šálek, MD PhD, Katerina Machova, Katerina Blagoevova, Jordi Ribera, PhD, Josep-Maria Ribera, MD PhD, Manja Meggendorfer, PhD, Claudia Haferlach, MD, Anna Guarini, PhD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 5211.

https://doi.org/10.1182/blood-2019-122116

Published: 2019

Journal Articles

The genetics of nodal marginal zone lymphoma

Blood (2016) 128 (10): 1362–1373.

https://doi.org/10.1182/blood-2016-02-696757

Published: 2016

Includes: Supplemental data

Journal Articles

Rapid Identification of BCR/ABL1 -like Acute Lymphoblastic Leukemia (ALL) Cases By Quantitative Real Time-PCR (Q-RT-PCR). Generation and Validation of a Predictive Statistical Model

Sabina Chiaretti, Sara Grammatico, Alfonso Piciocchi, Monica Messina, Anna Lucia Fedullo, Valentina Gianfelici, Grazia Fazio, PhD, Nadia Peragine, Maria Paola Martelli, Paola Fazi, Marco Vignetti, Antonella Vitale, Cyril Salek, Gianni Cazzaniga, PhD, Anna Guarini, Robin Foà

Blood (2015) 126 (23): 1410.

https://doi.org/10.1182/blood.V126.23.1410.1410

Published: 2015

Journal Articles

BIRC3 disruption and Copy Number Aberrations in Chronic Lymphocytic Leukemia (CLL) Patients with 11q Deletion

Blood (2014) 124 (21): 3295.

https://doi.org/10.1182/blood.V124.21.3295.3295

Published: 2014

Journal Articles

The Coding Genome of Nodal Marginal Zone Lymphoma Reveals Recurrent Molecular Alterations of PTPRD and Other Jak/Stat Signaling Genes

Blood (2014) 124 (21): 705.

https://doi.org/10.1182/blood.V124.21.705.705

Published: 2014

NARROW

Molecular Outcome of Chronic Myeloid Leukemia Affected Patients Not in Deep Molecular Response: The “Others” from the Gimema Labnet Network

Digital Twins As Control Groups to Accelerate Assessment of Safety and Efficacy of Novel Treatment Strategies in Ph-Negative Acute Lymphoblastic Leukemia

Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial

Evaluating the Impact of Cross-over from Imatinib to Nilotinib on the Overall Survival in Chronic Myeloid Leukemia Using Inverse Probability of Censoring Weighting: Results from the Gimema Sustrenim Study

Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial

LONG-TERM Results of the Frontline Dasatinib/Blinatumomabprotocol (D-ALBA, GIMEMA LAL2116) for Adult Ph+ Acutelymphoblastic Leukemia

A Propensity Score Weighting Analysis Emphasizes the Progress of the Gimema Approach in Adult Ph-Positive Acute Lymphoblastic Leukemia in the TKI Era

International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia (SUSTRENIM trial): Analysis of the Eligibility to Treatment Discontinuation

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

A Snapshot of the Management of Chronic Lymphocytic Leukemia in Italy. Preliminary Analysis on over 3000 Patients Enrolled in the Gimema CLL2121 Trial

Comparison between Dasatinib-Blinatumomab Vs Ponatinib-Blinatumomab Chemo-Free Strategy for Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia Patients. Preliminary Results of the Gimema ALLL2820 Trial

The Addition of Venetoclax to Induction Chemotherapy in No Low-Risk AML Patients: A Propensity Score-Matched Analysis of the Gimema AML1718 and AML1310 Trials

The Added Value of Multi-State Modelling in Acute Myeloid Leukemia: The Gimema AML1310 Study Post-Hoc Analysis

Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation

Prognostic Impact of t(4;11)(q21;q23)/ KMT2A-AFF1 -Positivity in 926 BCR-ABL1 -Negative B-Lineage Acute Lymphoblastic Leukemia Patients Treated in Gimema Clinical Trials Since 1996

The Validation of the BCR/ABL1 -like Predictor across Laboratories Shows Reproducibility of Results

The genetics of nodal marginal zone lymphoma

Rapid Identification of BCR/ABL1 -like Acute Lymphoblastic Leukemia (ALL) Cases By Quantitative Real Time-PCR (Q-RT-PCR). Generation and Validation of a Predictive Statistical Model

BIRC3 disruption and Copy Number Aberrations in Chronic Lymphocytic Leukemia (CLL) Patients with 11q Deletion

The Coding Genome of Nodal Marginal Zone Lymphoma Reveals Recurrent Molecular Alterations of PTPRD and Other Jak/Stat Signaling Genes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only